Lead Sponsor

Dong-A ST Co., Ltd.

Age

19 - No limit years

Sex

ALL

Healthy Volunteers

No

•Adult male and female subjects of ages in the range over 19
•The subjects HBsAg positive for at least 6 months or has history of Chronic Hepatitis B
•The subjects whose HBV DNA above 20,000 IU/mL when HBeAg positive or above 2,000 IU/mL when HBeAg negative or positive when has history of Chronic Hepatitis B
•The subjects completely understood the clinical trial through detailed explanation presented, determined to participate in the clinical trial spontaneously, and agreed to observe precautions suggested thereby through written consent

•The subjects who have been infected with HCV, HDV, HIV
•The subjects who have Hemochromatosis, Wilson's disease, autoimmune liver disease, and α-1 antitrypsin deficiency
•The subjects whose α-fetoprotein over 50 ng/mL and who are persumed to be Hepatocelluar carcinoma

Related studies

NCT07417553 · Chronic Hepatitis B-related Liver Fibrosis

NCT02932150 · Chronic Hepatitis B

NCT07024641 · Hepatitis B Virus Infection

NCT05856890 · Hepatitis b Virus, Hepatitis B

NCT06671093 · Chronic Hep B, Chronic Hepatitis b, and more

Clinical Study to Evaluate the Efficacy and Safety of DA-2803 in Chronic Hepatitis B Patients